This webinar focuses on HR+/HER2- breast cancer, featuring a distinguished panel of two expert physicians. This insightful event aims to delve into the diverse therapeutic approaches available for this specific subtype of breast cancer. Our esteemed panelists, with their extensive clinical experience and expertise, will discuss the latest advancements in treatment options, providing valuable insights into the evolving landscape of HR+/HER2- breast cancer management.

Join us as we explore the detailed aspects of therapeutic strategies, examine the latest research findings, and discuss potential future developments. This webinar offers a comprehensive overview of current treatment modalities, emphasizing their impact on patient outcomes and quality of life. This informative session is designed for healthcare professionals and individuals within the pharmaceutical industry. It offers a valuable opportunity for these professionals to enhance their understanding of HR+/HER2- breast cancer and stay updated on the evolving treatment landscape.

Joyce O’Shaughnessy – Baylor-Sammons Cancer Center

Joyce A. O’Shaughnessy, M.D. specializes in medical oncology with board certification in both internal medicine as well as medical oncology. She is a Diplomate of the American Board of Internal Medicine with subspecialty certification in medical oncology. Dr. O’Shaughnessy focuses on her practice and clinical research on breast cancer treatment. She is Director of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center and Chair of the Breast Disease Committee for Sarah Cannon Research Institute in Dallas, TX.

Adrienne Waks – Dana-Farber Cancer Institute

Adrienne G. Waks, MD, is an Assistant Professor of Medicine at Harvard Medical School and the Associate Director of Breast Oncology Clinical Research at Dana-Farber Cancer Institute. She specializes in breast cancer, immuno-oncology, and novel therapies for breast cancer. Dr. Waks received her medical degree from Harvard Medical School, completed her residency at Brigham and Women’s Hospital, including a year as Chief Resident, and finalized her fellowship in medical oncology at Dana-Farber/Partners CancerCare. She is board-certified in internal medicine and medical oncology.

Sign up below to view the webinar.